

# Session 5: Case Scenarios & Questions to Inform Development of a Risk Assessment Framework

## Two Breakout discussion groups:

### GROUP 1

#### New/Novel Excipients

- “Inactive” vs biologically active agents (e.g. SNAC)
- European vs. US approaches

### GROUP 2

#### Established / Standard Excipients

- Clarify what is known (experience) as it relates to the proposed setting
- Identify information gaps
- Identify alternative sources of information & the appropriateness thereof

incomplete information (eg, a new use, dose, duration, route, disease severity, age group, etc)

# Breakout session discussion

How to justify excipient use (novel, established) in paediatrics? What are the hurdles?

## Risk assessment & Information needs

- Can a **common template or approach** (framework) be developed for implementing risk assessments for individual excipients?
- What **minimum information** is required? What additional data is required?
- What circumstances and factors should be considered regarding the justification for **juvenile tox studies**?
- Should toxicology studies with the final formulation be conducted? If so, **when & which studies**?
- What **alternative options** are available if no additional information is available?
- What **clinical trial design factors** can be incorporated to provide information on the safety of excipients?
- Where are the **knowledge gaps** and how would you **prioritize studies needed** to approach the evaluation of excipients for paediatrics?

## Information sharing platform

- Where to find the existing information?
  - Platform to share information? (eg, STEP database)
  - extending the FDA inactive ingredient database to paediatrics

## Proposed Framework – Your opinion matters!!

- Would the proposed framework help address the issues of use of excipients in paediatrics?
  - What are the **pros and cons** of the presented framework ?
  - What **additional elements** would you consider in the framework?
- Can we evaluate data on excipients & present in a format which will satisfy regulators?

# Breakout Deliverable: Proposed Framework to Assess Safety; Needs, Possible Solutions

1. Is the use of the excipient justified?
2. Is there an established regulatory guideline or opinion?
3. Is there relevant prior human use? (pharma, food)
4. Is there other supporting information?
  - Clinical – Adult, Paediatric, PK, PD, Modeling
  - Nonclinical – Toxicology, PK/PD
  - Similarity to other excipients?
5. Trials/Studies to fill the gaps
  - Design, Value

Consider relevance to intended Age, Route, Dose, Duration, Disease, etc ...  
What are the Gaps?

- What are the **pros and cons** of the presented framework?
- What **additional elements** would you consider in the framework?

Better info sharing?